8:15 am Virtual Coffee Room Opens

8:45 am Chair’s Opening Remarks

Understanding & Overcoming Relapse with Multi-Targeting Therapies

9:00 am Investigating Mechanisms of Resistance and Relapse in Patients to Devise Rational Multi-Targeting Strategy

  • John Rossi Senior Director Translational Science, Kite: A Gilead Company

9:30 am Using the DNA Damage Response as a Mechanism of Cell Targeting with Alkylating Agents, Gamma-Delta T cells, and Logical Additions to Combination Therapy

10:00 am Developing Parallel CAR-T for Increased Efficacy

10:30 am Speed Networking

Multi-Modal Therapies to Enhance Tumor Infiltration

11:00 am Engineering CAR-T Cells with Immune Enhancers under the Control of Molecular Switches for Tunable Dosing and Enhanced Tumor Clearance

11:30 am Sculpting the Immune System Through Multi-Moiety Therapy

12:00 pm Highly Specific TCR-Mimics Based on the DARPin Technology with Potential for Multi-Targeted T Cell Responses and Possible Future Applications for T Cell Based Therapies

12:30 pm Lunch & Networking

1:30 pm Developing ARTEMIS T cells, a Novel CAR-TCR Hybrid with Enhanced Specificity and Tumor Infiltration in Solid Tumors

  • Cheng Liu President & CEO, Eureka Therapeutics, Inc

2:00 pm Combinatorial specificity profiling and engineering to safeguard and optimize TCR reactivity

2:30 pm Enhancing Solid Tumor CAR T and TCR Therapy Using Amphiphile Technology

2:50 pm Leveraging Site-Specific Targets to Optimize Trafficking Mitigate On-Target, Off-Tumor Effects

Next Steps to Advance Multiplexed Cell Therapies

3:10 pm Expert Speaker Q&A: Strategies to Drive Tumor Infiltration and Minimize On-Target, Off-Tumor Effects with Co-Stimulatory Domains and Enhancers

3:30 pm Afternoon Poster Session

4:00 pm Pharmacological Control of CAR T Cell Therapies

4:30 pm Roundtable: Addressing Regulatory Requirements and Hurdles when Developing Multi-Targeted Therapies

5:00 pm Realizing Multi-Targeting from a Manufacturing Perspective to Deliver Better Therapies More Efficiently

5:30 pm Chair’s Closing Remarks

5:45 pm End of Day 1